Dosing & Uses
Dosage Forms & Strengths
Indicated as adjunct to diet for severe hypertriglyceridemia (>500 mg/dL)
Individualize dose according to patient response
Antara: 30-90 mg PO qDay
Lofibra capsules: 67-200 mg PO qDay
Primary Hypercholesterolemia or Mixed Lipidemia
Indicated as adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia
Antara: 90 mg PO qDay initially; discontinue if inadequate response after 2 months of treatment; may decrease dose if patient responds
Lofibra capsules: 200 mg PO qDay
- Mild-to-moderate (CrCl 30-80 mL/min): Initiate at lowest available dose and increase only after evaluating effects on renal function and lipid levels
- Severe (CrCl <30 mL/min): Contraindicated
Hypertriglyceridemia: Improving glycemic control in diabetic patients with fasting chylomicronemia will usually obviate the need for pharmacological intervention
Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus
Antara: May take with or without meals
Lofibra capsules: Take with meals to optimize bioavailability
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Abdominal pain (4.6%)
Back pain (3.4%)
Increased AST (3.4%)
Increased ALT (3%)
Increased CPK (3%)
Myalgia, rhabdomyolysis, muscle spasms, arthralgia
Severely depressed HDL levels
Severe renal impairment (including dialysis)
Active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities
Pre-existing gallbladder disease
Effect on coronary heart disease morbidity and mortality not established
Increases risk of myositis or myopathy, and has been associated with rhabdomyolysis; risk may increase when coadministered with statins
Higher doses or coadministration with statins associated with increased serum transaminases
May increase serum creatinine
May increase cholesterol excretion in bile, potentially leading to cholelithiasis
Coadministration with warfarin may increase anticoagulant effects resulting in PT/INR prolongation
Pancreatitis reported; may be a failure of efficacy with severe hypertriglyceridemia, a direct drug effect, or secondary effect via biliary stone or sludge formation
May decrease hemoglobin, hematocrit, and leukocytes
Thrombocytopenia and agranulocytosis reported
Acute hypersensitivity reactions (eg, Stevens-Johnson syndrome, toxic necrolysis) reported PE and DVT reported
Paradoxical decreases in HDL cholesterol reported
Pregnancy & Lactation
Pregnancy Category: C
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Fenofibrate is a prodrug that is metabolized to the active moiety, fenofibric acid
Activates peroxisome proliferator activated receptor-alpha (PPAR-alpha); increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reduces Apo CIII production (lipoprotein lipase inhibitor)
Reduces TC, LDL-C, Apo B, TG, and VLDL; increases HDL-C, Apo AI, and Apo AII
Peak Plasma Time: 4-8 hr (fenofibric acid)
Time to steady-state: within 7 days (Antara); within 5 days (Lofibra capsules)
Protein Bound: 99%
Fenofibrate converted by ester hydrolysis to fenofibric acid (active moiety)
Fenofibric acid is primarily conjugated with glucuronic acid; a small amount is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid
Half-life: 20-23 hr
Excretion: 66% in urine, primarily as fenofibric acid and fenofibric acid glucuronide; 25% feces
Genotyping patients with atherogenic dyslipidemia might establish who will benefit most from therapy with fenofibric to increase HDL-C
Three single-nucleotide polymorphisms (SNPs) in the APOA5 region have been associated with increases in HDL-C
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.